Literature DB >> 12073047

Expression of survivin in primary glioblastomas.

Asha Das1, Wan-Loo Tan, Jennifer Teo, Duncan R Smith.   

Abstract

PURPOSE: Studies in several tumour types have suggested that the inappropriate expression of the novel inhibitor of apoptosis protein survivin may play a key role in tumourigenesis. This study presents the first immunohistochemical examination of survivin expression in glioblastomas.
METHOD: The cohort consisted of 39 ethnic Chinese patients diagnosed with primary glioblastoma multiforme. Samples were archival paraffin-embedded blocks. Concomitant with examination for survivin expression, samples were also examined for over-expression of the p53 protein as well as for evidence of apoptotic cells via the terminal deoxynucleotide transferease (TdT) mediated nick end labelling (TUNEL) technique.
RESULTS: Results showed that survivin was expressed in nearly 80% (31/39) of samples. Over-expression of moderate or high levels of survivin was correlated with the absence of apoptotic cells ( P=0.03). Expression of survivin and p53 was found to be significantly related ( P=0.037), and 70% (27/39) of tumours showed co-ordinate expression of p53 and survivin.
CONCLUSION: Given that p53 over-expression in primary glioblastomas is predominantly detected in the absence of mutations of the gene, and that both survivin and p53 are regulated at the level of the protein by the same ubiquitin-proteosome degradation pathway, these results suggest that primary glioblastomas may occur as a result of a failure of appropriate protein degradation regulation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12073047     DOI: 10.1007/s00432-002-0343-4

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  20 in total

1.  Knockdown of survivin gene expression by RNAi induces apoptosis in human hepatocellular carcinoma cell line SMMC-7721.

Authors:  Sheng-Quan Cheng; Wen-Liang Wang; Wei Yan; Qing-Long Li; Li Wang; Wen-Yong Wang
Journal:  World J Gastroenterol       Date:  2005-02-07       Impact factor: 5.742

2.  Oncolytic adenoviral vectors which employ the survivin promoter induce glioma oncolysis via a process of beclin-dependent autophagy.

Authors:  Ilya V Ulasov; Mathew A Tyler; Zeng B Zhu; Yu Han; Tong-Chuan He; Maciej S Lesniak
Journal:  Int J Oncol       Date:  2009-03       Impact factor: 5.650

3.  Nuclear survivin expression predicts poorer prognosis in glioblastoma.

Authors:  Katsuyuki Shirai; Yoshiyuki Suzuki; Kuniyuki Oka; Shin-ei Noda; Hiroyuki Katoh; Yoshihiko Suzuki; Jun Itoh; Hideaki Itoh; Shogo Ishiuchi; Hideyuki Sakurai; Masatoshi Hasegawa; Takashi Nakano
Journal:  J Neurooncol       Date:  2008-10-25       Impact factor: 4.130

4.  Targeting mesothelioma using an infectivity enhanced survivin-conditionally replicative adenoviruses.

Authors:  Zeng B Zhu; Sharmila K Makhija; Baogen Lu; Minghui Wang; Shuyi Wang; Koichi Takayama; Gene P Siegal; Paul N Reynolds; David T Curiel
Journal:  J Thorac Oncol       Date:  2006-09       Impact factor: 15.609

5.  p53 expression and subcellular survivin localization improve the diagnosis and prognosis of patients with diffuse astrocytic tumors.

Authors:  Roberta Soares Faccion; Paula Sabbo Bernardo; Giselle Pinto Faria de Lopes; Leonardo Soares Bastos; Cristina Lordello Teixeira; José Antonio de Oliveira; Priscila Valverde Fernandes; Luiz Gustavo Dubois; Leila Chimelli; Raquel Ciuvalschi Maia
Journal:  Cell Oncol (Dordr)       Date:  2018-01-26       Impact factor: 6.730

6.  Tissue transgluaminase 2 expression in meningiomas.

Authors:  Liya Yuan; Amir Behdad; Matthew Siegel; Chaitan Khosla; Ryuji Higashikubo; Keith M Rich
Journal:  J Neurooncol       Date:  2008-06-28       Impact factor: 4.130

7.  Autologous CMV-specific T cells are a safe adjuvant immunotherapy for primary glioblastoma multiforme.

Authors:  Corey Smith; Katie E Lineburg; J Paulo Martins; George R Ambalathingal; Michelle A Neller; Beth Morrison; Katherine K Matthews; Sweera Rehan; Pauline Crooks; Archana Panikkar; Leone Beagley; Laetitia Le Texier; Sriganesh Srihari; David Walker; Rajiv Khanna
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

Review 8.  Adenoviral virotherapy for malignant brain tumors.

Authors:  Suvobroto Nandi; Maciej S Lesniak
Journal:  Expert Opin Biol Ther       Date:  2009-06       Impact factor: 4.388

Review 9.  Stem cells as delivery vehicles for oncolytic adenoviral virotherapy.

Authors:  Justin Kranzler; Matthew A Tyler; Adam M Sonabend; Ilya V Ulasov; Maciej S Lesniak
Journal:  Curr Gene Ther       Date:  2009-10       Impact factor: 4.391

10.  Effects of JC virus infection on anti-apoptotic protein survivin in progressive multifocal leukoencephalopathy.

Authors:  Sergio Piña-Oviedo; Katarzyna Urbanska; Sujatha Radhakrishnan; Thersa Sweet; Krzysztof Reiss; Kamel Khalili; Luis Del Valle
Journal:  Am J Pathol       Date:  2007-04       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.